UK Biobank | GenomeWeb

UK Biobank

While the new methods were developed specifically to address the UKBB's needs, Affymetrix believes the approaches will set a precedent for industrial-scale genotyping.

The UK Biobank will use Trinean's technology to quantify molecules during the DNA extraction stage of a large genotyping project.

This article was originally posted on Oct. 25.
BOSTON – Customers who are interested in using Illumina's highest-content genotyping arrays will soon be able to do so at a reduced cost.

The UK Biobank and Affymetrix recently finished developing an array that will be used to genotype all 500,000 samples in UKBB's biorepository.

This story was originally posted on Aug. 1.
Affymetrix posted a 20 percent rise in second-quarter revenues last week, largely due to a contribution from its eBioscience business, but also driven by double-digit growth in genotyping array sales.

Name: Mark McCarthy
Title: Robert Turner Professor of Diabetes, University of Oxford

This article was originally posted on May 1.
An unanticipated decline in demand for gene expression microarrays has thwarted Affymetrix's return to growth and profitability and caused the firm to suspend its 2013 guidance, executives said last week.

Name: Andrew Brooks
Title: Chief operating officer, RUCDR Infinite Biologics

Affymetrix and the UK Biobank last week announced an agreement that will see the array vendor genotype UKBB's collection of 500,000 samples.

NEW YORK (GenomeWeb News) – Affymetrix today announced a contract with UK Biobank to genotype 500,000 DNA samples as part of a study of complex diseases.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.